Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Phase 1 positivity in insomnia, depression
March 2016
EDIT CONNECT

SHARING OPTIONS:

WALTHAM, Mass.—Biopharmaceutical company Minerva Neurosciences Inc. recently shared top-line results from a Phase 1 clinical trial of MIN-202 (JNJ-42847922) in Japan. The compound is a selective orexin-2 receptor antagonist under joint development with Janssen Pharmaceutica NV as a treatment for patients with insomnia disorder and as adjunctive treatment to concomitant antidepressant drug therapy in major depressive disorder. MIN-202 was well tolerated at all three dose levels tested, with no clinically relevant safety concerns. Minerva and Janssen began a co-development and license agreement in February 2014 that covers MIN-202 and any other orexin-2 compounds.
 
“These findings are an important step in the global development of MIN-202,” said Dr. Remy Luthringer, president and CEO of Minerva. “They add to the expanding database of study participants treated with this compound worldwide and support further clinical testing in an important part of the world.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.